TD Cowen analyst Marc Frahm has maintained their bullish stance on ADAP stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

Detailed price information for Black Diamond Therapeutics Inc (BDTX-Q) from The Globe and Mail including charting and trades.

Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Black Diamond ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $15.6 million in its third quarter. The Cambridge, Massachusetts-based company ...

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 ...

Going into the colder months with a bang.If you're hoping to switch it up at your next hair appointment with some bold bangs, ...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

On Tuesday, Black Diamond Therapeutics (NASDAQ:BDTX) shares maintained its Buy rating and $11.00 price target from H.C. Wainwright. The biotechnology company, focused on precision... On Monday, TD ...

On Tuesday, Black Diamond Therapeutics Inc (BDTX) stock saw a decline, ending the day at $2.86 which represents a decrease of $-0.06 or -2.05% from the prior close of $2.92. The stock opened at $2.88 ...